Rat Glicentin ELISA Kit (DEIA4588)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
citrate plasma, EDTA plasma, heparin plasma
Species Reactivity
Rat
Intended Use
This EIA kit is used for quantitative determination of rat glicentin in plasma sample.
Contents of Kit
1. Antibody coated plate, 1 plate (96 wells), Goat anti rabbit IgG
2. Glicentin Standard, lyophilized, 1 vial, Synthetic rat glicentin (50 pmol)
3. Labeled antigen, lyophilized, 1 vial, Biotinylated rat glicentin
4. Glicentin antibody, liquid, 1 bottle (6 mL), Rabbit anti rat glicentin
5. SA-HRP solution, liquid, 1 bottle (12 mL), HRP labeled streptoavidin
6. Substrate buffer, liquid, 1 bottle (26 mL), 0.015% Hydrogen Peroxide
7. OPD tablet, 2 tablets o-Phenylenediamine hydrochloride
8. Stopping solution, liquid, 1 bottle (12 mL), 1M-H2SO4
9. Buffer solution, liquid, 1 bottle (10 mL), Phosphate buffer
10. Washing Solution (concentrated), liquid, 1 bottle (50 mL), Concentrated saline
Storage
Store all of the components at 2-8°C.
Precision
Intra-assay CV (%): 4.6-7.8
Inter-assay CV (%): 3.2-7.6

Citations


Have you cited DEIA4588 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY(3-36)and glucagon-like peptide-1 levels, hunger or satiety

DIABETES OBESITY & METABOLISM

Authors: Nguyen, Nga N.; Kolobova, Irina; Wolfe, Bruce M.; Purnell, Jonathan Q.

Fat malabsorption associated with Roux-en-Y gastric bypass (RYGB) may contribute to elevated postprandial glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) after the procedure, leading to sustained weight loss and appetite reduction. This study investigated whether fat malabsorption via orlistat increases GLP-1 and PYY and if these increases would be proportional to changes in hunger and satiety. Five healthy participants received standardized meals with 120 mg orlistat or placebo in a randomized, double-blinded, crossover design for 3 days. On the final day, glucose, insulin, GLP-1, PYY(3-36)and visual analogue scores for hunger and satiety were measured over a 14-hour period that included three meals. Fasting, 14-hour area under the curve (AUC) and meal-related AUC for glucose and insulin were similar, although postprandial increases in peak insulin and glucose were greater with orlistat. PYY3-36, GLP-1, hunger and satiety were not different. In conclusion, short-term orlistat administration does not enhance postprandial GLP-1 or PYY(3-36)or affect hunger or satiety in normal-weight individuals. Furthermore, fat malabsorption from RYGB is unlikely to mediate subsequent postprandial increases in GLP-1 and PYY.

European Pediatric Surgeon' Association Survey on the Management of Short-Bowel Syndrome

EUROPEAN JOURNAL OF PEDIATRIC SURGERY

Authors: Dariel, Anne; Faure, Alice; Martinez, Leopoldo; Morini, Francesco; Pini Prato, Alessio; Friedmacher, Florian; Coste, Marie-Edith

Introduction The aim of this study was to assess the management of short-bowel syndrome (SBS) at the time of primary surgery, and the strategies used to facilitate enteral autonomy depending on the institutional expertise. Materials and Methods An online questionnaire was sent in 2019 to members of The European Pediatric Surgeons' Association. Results Among the 65 responding members (26 countries, 85% from university hospitals), 57% manage less than three new patients with SBS per year (group A), and 43% at least three patients (group B). The cut-off of three patients treated yearly used in our study was defined after statistical analysis of different cut-offs. A multidisciplinary intestinal rehabilitation program is significantly more frequent in group B than in group A (85 and 53%, respectively; p =0.009). Considering the primary surgical management of multiple intestinal atresia and congenital ultra-short bowel with jejunal atresia, primary surgical strategies to optimize bowel length are more often used in group B than group A ( p =0.09 and p =0.04, respectively). A minimum of one intestinal lengthening procedure every 2 to 3 years is significantly more frequent in group B than group A (95 and 45%, respectively; p =0.0013). Among the strategies used to promote intestinal adaptation, group B (35%) uses significantly more often glucagon-like peptide 2 analogs than group A (10%) ( p =0.02). Conclusion Based on our survey, a minimum number of SBS patients treated yearly is required to manage this challenging disease according to up-to-date medical and surgical strategies. However, whatever their level of expertise is in managing SBS, most of pediatric surgeons are involved in the primary surgery. Medical education programs about SBS should be more largely available to pediatric surgeons.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket